CBT's Quality Score rose 2 points on Tue, Nov 10, to 1. It closed near its high of the day (2 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 6% over three years while the S&P 500 rose 80%; up 21% in the past year.
| Holding it back | Below its 200-day since September |
| Latest filing | 8-K, Nov 2 |
After its last 4 reports it closed +0.4% on average, higher 2 of 4 times.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
CBT is #5 of 7 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 3 | ||
| 4 | ||
| 5 | ||
| Open for its score | ||
| Open for its score |
Sales over four quarters against a year before: CBT -4.7%, ESI +40%, WDFC +11%.
Expected to report Mon Feb 1, after the close (in 83 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $1.25 a share, from $0.79.
“Net income reflects an after-tax per share charge from certain items of $0.36, primarily related to charges for restructuring actions.”
CBT's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Adjusted EPS | $6.15 to $6.75 |
“The decline in EBIT was primarily driven by lower gross profit per ton, which was partially offset by higher volumes.”
From its results filing (SEC filing · Nov 2)
Sales grew 7.3% a year over 5 years, fiscal 2020 to 2025.
Pays $1.89 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -7.0% | -4.9% | -5.1% |
| Aug 3, 2026 | -9.4% | -8.5% | -3.5% |
| May 5, 2026 | +5.1% | +4.4% | +7.1% |
Sales grew in four of the last seven years, to $3.7B in 2025. It made a profit in six of the eight years.
RSI 42.2, MACD below signal, below both averages. Not scored.
Its dividends come to 35% of its free cash flow.
| Dividend | $1.89 a share a year |
| Paid out | About $97.6M a year |
| Free cash flow | $281M |
| Record | Raised each of the last 5 years |
One insider sold $19.6M across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CBT is under 0.1% of DGRO, under 0.1% of VIG, and under 0.1% of VYM, the most of the 24 funds Breakaway covers, by their holdings as filed for Jul 31, 2026.
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.
“We compete in the sale of reinforcing carbons with four companies that operate globally and numerous other companies that operate regionally, a number of which export product outside their region of manufacture.”
CBT scores 1 today, which Breakaway calls Below Average. It is #5 of 7 in Miscellaneous Chemical Products by Quality Score, with 3 of 14 chart checks firing. Up 6% over three years while the S&P 500 rose 80%; up 21% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CBT scores 1 today, which Breakaway calls Below Average (0 to 5). That is #5 of 7 in Miscellaneous Chemical Products by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CBT's 1.
One insider sold $19.6M across 3 filings in the last 6 months. No open-market buys on record. The newest is Sean D. Keohane, President and CEO, who sold $11.5M on Aug 28. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.